Home/Pipeline/TZIELD®

TZIELD®

Stage 2 "At Risk" Type 1 Diabetes

MarketedCommercial

Key Facts

Indication
Stage 2 "At Risk" Type 1 Diabetes
Phase
Marketed
Status
Commercial
Company

About MacroGenics

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop life-changing medicines for patients with cancer. The company has built a broad pipeline of investigational product candidates, including its lead bispecific DART® molecule lorigerlimab, and has established strategic collaborations with global pharmaceutical companies. With in-house GMP manufacturing capabilities and a focus on innovative antibody engineering, MacroGenics aims to address significant unmet needs in oncology.

View full company profile

About MacroGenics

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop life-changing medicines for patients with cancer. The company has built a broad pipeline of investigational product candidates, including its lead bispecific DART® molecule lorigerlimab, and has established strategic collaborations with global pharmaceutical companies. With in-house GMP manufacturing capabilities and a focus on innovative antibody engineering, MacroGenics aims to address significant unmet needs in oncology.

View full company profile